Gut microbiota and hepatic encephalopathy (Q34609555)

3 August 2017

title

Gut microbiota and hepatic encephalopathy (English)

1 reference

3 August 2017

Radha K Dhiman

1

1 reference

3 August 2017

publication date

6 March 2013

1 reference

3 August 2017

published in

Metabolic Brain Disease

1 reference

3 August 2017

volume

28

1 reference

3 August 2017

issue

2

1 reference

3 August 2017

page(s)

321-326

1 reference

Probiotic yogurt for the treatment of minimal hepatic encephalopathy.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Linkage of gut microbiome with cognition in hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Hepatic encephalopathy: A central neuroinflammatory disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Characterization of fecal microbial communities in patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Minimal hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Gut microbiota and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Rifaximin for the treatment of hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Changing face of hepatic encephalopathy: role of inflammation and oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Role of ammonia and inflammation in minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Probiotics can treat hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Endotoxemia produces coma and brain swelling in bile duct ligated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11011-013-9388-0

Probiotics for patients with hepatic encephalopathy

21 January 2018

1 reference

12 December 2020

Molecular characterization of the bacteria adherent to human colorectal mucosa

1 reference

12 December 2020

[Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonisation, endo-toxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis]

1 reference

12 December 2020

Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy

1 reference

12 December 2020

Myth: interpretation of a single ammonia level in patients with chronic liver disease can confirm or rule out hepatic encephalopathy.

1 reference

12 December 2020

Minimal hepatic encephalopathy: consensus statement of a working party of the Indian National Association for Study of the Liver

1 reference

12 December 2020

Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study

1 reference

12 December 2020

Gut flora-based therapy in liver disease? The liver cares about the gut

1 reference

12 December 2020

Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy

1 reference

12 December 2020

Effects of lactulose treatment on the course of subclinical hepatic encephalopathy

1 reference

12 December 2020

Pathogenesis, diagnosis, and treatment of hepatic encephalopathy

1 reference

12 December 2020

Probiotics, prebiotics, and synbiotics--approaching a definition

1 reference

12 December 2020

Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy

1 reference

12 December 2020

Systemic inflammation and ammonia in hepatic encephalopathy.

1 reference

12 December 2020

Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation

1 reference

12 December 2020

Gut microbiota, inflammation and hepatic encephalopathy: a puzzle with a solution in sight

1 reference

12 December 2020

Prognostic significance of hepatic encephalopathy in patients with cirrhosis

1 reference

12 December 2020

10.1007/S11011-013-9388-0

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1026048717

0 references

Fatcat ID

release_qwxg5d5y5fdl5irracxg5urv2y

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qwxg5d5y5fdl5irracxg5urv2y

24 November 2022

mapped directly with Wikidata item

1 reference